{"prompt": "['MC1752', '12', '2.0', 'Goals', '2.1', 'Primary Goal', '2.11', 'To evaluate the complete response rate of concurrent chemotherapy radiation', 'treatment combined with avelumab for patients with muscle invasive bladder', 'cancer.', '2.2', 'Secondary Goals', '2.21', 'To evaluate the safety and toxicity (adverse event profile) of concurrent', 'chemotherapy radiation treatment combined with avelumab.', '2.22', 'To evaluate quality of life (QoL) at 1 year of concurrent chemotherapy radiation', 'treatment combined with avelumab.', '2.23', 'To evaluate progression-free survival and relapse-free survival at 1 year with', 'concurrent chemotherapy radiation treatment combined with avelumab.', '2.3', 'Correlative Research', '2.31', 'To explore biomarkers that may predict response to avelumab in the muscle', 'invasive population. The following markers will be tested:', 'Expression of PD-L1 and CD8 by immunohistochemistry (IHC)', 'Expression of immune signatures by RNA-sequencing (RNA-seq).', 'To evaluate the association of tumor mutational burden with response to', 'concurrent chemo- radiation and immunotherapy', 'To evaluate whether concurrent chemoradiation and immunotherapy after', 'maximal TURBT is associated with a decrease in circulating Bim CD11a highpD-', '1tCD8+ T-cells and MDSCs.', 'Protocol Version Date: 21JUN2018']['MC1752', '13', '3.0', 'Registration Patient Eligibility', 'For the run-in portion only, prior to discussing protocol entry with the patient, call the', 'MCCC Registration Office', 'to insure that a place on the protocol is open to', 'the patient.', '3.1', 'Registration - Inclusion Criteria', '3.11', 'Age >18 years.', '3.12', 'Histologic proof of T2-T4a NOMO (AJCC 8th edition ) with predominant', 'urothelial carcinoma. Mixed histologies are acceptable provided urothelial', 'carcinoma is the predominant histology. Small cell urothelial carcinoma is', 'excluded.', '3.13', 'Cystoscopy with maximal TURBT performed < 70 days of study registration.', 'NOTE: Both completely resectable or partially resectable tumors are eligible as', 'long as the treating urologist attempted complete resection. Exam under', 'anesthesia needs to be performed and documented.', '3.14', 'The following laboratory values obtained < 28 days prior to registration.', 'ANC 1500/mm\u00b3', 'PLT 100,000/mm\u00b3', 'Total bilirubin < 1.5 upper limit of normal (ULN)', 'Aspartate transaminase (AST) < 2.5 X ULN (<5 x ULN for patients with liver', 'involvement)', 'Alanine Aminotransferase (ALT) < 2.5 X ULN (<5 x ULN for patients with', 'liver involvement)', 'Hgb > 9 gm/dl', 'Calculated creatinine clearance must be > 30 ml/min using the Cockcroft-', 'Gault formula below:', 'Cockcroft-Gault Equation:', 'Creatinine clearance for males =', '(140-age)(weight - in kg)', '(72)(serum creatinine in mg/dL)', 'Creatinine clearance for females =', '(140-age)(weight - in kg)(0.85)', '72)(serum creatinine in mg/dL)', '3.15', 'ECOG Performance Status (PS 0, 1, 2) (Appendix I).', '3.16', 'Ability to provide informed written consent.', '3.17', 'Willing to return to enrolling institution for follow-up (during the Active', 'Monitoring Phase of the study).', '3.18', 'Life expectancy > 6 months.', '3.19', 'Negative serum pregnancy test done < 14 days prior to registration, for women of', 'childbearing potential only.', '3.2', 'Registration - Exclusion criteria', '3.21', 'Patients with locally advanced unresectable (T4b) or metastatic urothelial', 'carcinoma (N1M0-1) as assessed on baseline radiographic imaging obtained < 70', 'days prior to study registration. The required radiographic imaging includes:', 'Protocol Version Date: 21JUN2018']['MC1752', '14', 'Abdomen/Pelvis CT or MRI scan', 'Chest x-ray or CT scan', '3.22', 'Patients with concurrent urothelial carcinoma and/or related variants anywhere', 'outside bladder', 'NOTE: Patients with history of non-invasive (Ta, Tis) upper tract urothelial', 'carcinoma that has been definitively treated with at least one post-treatment', 'disease assessment (i.e. cytology, biopsy, imaging) that demonstrates no', 'evidence of residual disease are eligible.', '3.23', 'A prior or concurrent malignancy of any other site or histology unless the patient', 'has been disease-free for > 2 years prior to registration except for:', 'non-melanoma skin cancer and/or localized prostate cancer(* T2 a or b,', 'Gleason <3+4) or carcinoma in situ of the uterine cervix which has been', 'adequately treated 2 years prior to registration', 'or undergoing active surveillance per standard-of-care management (e.g.,', 'chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason', 'score 3+4, and prostate-specific antigen [PSA]  10 mg/mL, etc.)', '3.24', 'Patients who have received the last administration of an anti-cancer therapy', 'including chemotherapy, immunotherapy, and monoclonal antibodies < 4 weeks', 'prior to registration, or who have not recovered from the side effects of such', 'therapy.', 'EXCEPTION: Except single dose intravesical chemotherapy administered after', 'TURBT.', '3.25', 'Patients who have received prior therapy with immune checkpoint inhibitors (e.g.', 'anti-PD-1, anti-PD-L1, anti-LAG3, anti-CTLA-4, anti-TIM3) or immune', 'costimulatory molecules (e.g. anti-CD137, anti-OX40, anti-GITR) directed', 'agents.', '3.26', 'Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal', 'or intra-pelvic), open biopsy or significant traumatic injury < 4 weeks prior to', 'registration, or who have not recovered from side effects of such procedure or', 'injury prior to registration.', 'NOTE: Patients who have had minor procedures (i.e. TURBT) or percutaneous', 'biopsies prior to registration are eligible.', '3.27', 'Patients with history of cirrhosis, alcoholic or non-alcoholic steatohepatitis', '(NASH), auto-immune hepatitis, or previous grade 3-4 drug-related hepatitis.', '3.28', 'Patient with history of prior solid organ or allogeneic bone marrow transplant.', '3.29', 'Clinically significant cardiac diseases, including any of the following:', 'History or presence of serious uncontrolled ventricular arrhythmias', 'Clinically significant resting bradycardia', 'Any of the following < 3 months prior to registration: myocardial infarction', '(MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG),', 'Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA),', 'Transient Ischemic Attack (TIA), Pulmonary Embolism (PE)', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}